List of Excipients in Branded Drug ILUVIEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	ILUVIEN	fluocinolone acetonide	68611-190	POLYVINYL ALCOHOL
ANI Pharmaceuticals Inc	ILUVIEN	fluocinolone acetonide	68611-190	WATER

ILUVIEN excipient strategy is based on a non-bioerodible intraocular implant rather than a conventional formulation. The product contains 190 micrograms of fluocinolone acetonide in a polyimide tube sealed with silicone adhesive and delivered through a single-use applicator. Commercial opportunities are concentrated in implant materials, rate-control engineering, applicator systems, manufacturing services, and follow-on products rather than in conventional excipient substitution.

Last updated: August 29, 2026

ILUVIEN Excipient Strategy, Patent Protection, and Commercial Opportunities

What is ILUVIEN and how does its formulation work?

ILUVIEN is an intravitreal implant containing fluocinolone acetonide for the treatment of diabetic macular edema in patients previously treated with corticosteroids who did not experience a clinically significant rise in intraocular pressure. Alimera Sciences developed the product; ANI Pharmaceuticals acquired Alimera in 2024.[1,2]

The U.S. product contains:

Product attribute	ILUVIEN specification
Active pharmaceutical ingredient	Fluocinolone acetonide
Drug load	190 micrograms
Route	Intravitreal implantation
Nominal duration	Up to 36 months
Implant type	Non-bioerodible cylindrical reservoir
Implant dimensions	Approximately 3.5 mm long and 0.37 mm in diameter
Drug delivery rate	Approximately 0.2 micrograms per day
Delivery system	Single-use preloaded applicator
Primary materials	Polyimide tube and silicone adhesive
FDA regulatory pathway	New Drug Application
U.S. approval	2014
Main commercial owner	ANI Pharmaceuticals following acquisition of Alimera Sciences

ILUVIEN does not use a conventional aqueous vehicle, lipid system, polymeric microsphere, or biodegradable depot. The formulation strategy places the drug inside a small reservoir. The implant materials regulate release and maintain physical integrity after implantation.

The principal formulation value comes from controlled delivery over an extended period. The materials surrounding the API are therefore closer to device components than to conventional tablet or injectable excipients.

What excipients and device materials are used in ILUVIEN?

The FDA-approved product identifies fluocinolone acetonide as the active ingredient and uses polyimide and silicone-based materials in the implant and delivery system.[1]

Polyimide reservoir

Polyimide is the principal structural material in the implant. It provides:

• Mechanical strength during implantation.
• Dimensional stability in the vitreous environment.
• A defined reservoir for the drug substance.
• Compatibility with a small-diameter ocular implant.
• A surface that can be sealed at the implant ends.

Polyimide selection is commercially important because molecular weight, wall thickness, curing history, surface treatment, and dimensional tolerances can affect drug release and manufacturing yield.

A generic developer would not be able to treat polyimide as a freely interchangeable excipient. A material change could alter:

• Fluocinolone diffusion.
• Water ingress.
• Drug crystallinity.
• Implant strength.
• Particulate generation.
• Extractables and leachables.
• Sterilization stability.
• Tissue response.

Silicone adhesive or sealant

Silicone is used to seal the reservoir and maintain implant integrity. Its performance depends on the chemical composition, cure conditions, adhesion to polyimide, and residual low-molecular-weight species.

The silicone component creates several development requirements:

• Biocompatibility testing under ocular-use conditions.
• Control of uncured or extractable siloxanes.
• Validation of the seal against long-term fluid ingress.
• Demonstration that the adhesive does not change fluocinolone release.
• Particulate and endotoxin control.
• Sterilization compatibility.

Silicone substitution could create a clinically relevant product difference even if the drug load and implant dimensions remain unchanged.

Polyvinyl alcohol and related materials

Polyvinyl alcohol is associated with several ophthalmic implant technologies, but the exact inactive-material composition must be tied to the applicable country-specific label and product configuration. A developer should not assume that an excipient identified in one ocular implant is present in ILUVIEN.

This distinction matters because ILUVIEN is marketed in multiple jurisdictions, and formulation descriptions can differ between U.S. labeling, European technical documentation, and manufacturing specifications.

How does ILUVIEN’s controlled-release mechanism create commercial opportunities?

ILUVIEN’s release profile is the result of a combined API-material-device system. The main commercial opportunities are therefore specialized.

Implant-grade polymer supply

Potential suppliers can compete for:

• Medical-grade polyimide tubing.
• Precision extrusion.
• Micromachining and cutting.
• Surface cleaning and treatment.
• Implant-end capping.
• Dimensional inspection.
• Low-particulate manufacturing.

The relevant market is narrower than the market for common pharmaceutical excipients such as lactose, mannitol, or polysorbate 80. Supplier qualification is more difficult because the material becomes part of an implanted drug-delivery system.

Silicone formulation and sealing services

A supplier with validated medical-grade silicone chemistry could pursue:

• Custom sealant systems.
• Low-extractables silicone formulations.
• Automated dispensing.
• Controlled curing.
• Seal-integrity testing.
• Contract manufacturing of capped reservoirs.

The strongest opportunity is not a simple replacement material. It is a validated sealing process that improves yield, reduces defects, or supports a differentiated release profile without increasing ocular risk.

Drug-loading and microassembly

ILUVIEN requires precise loading of a small amount of fluocinolone acetonide into a narrow implant. Commercial opportunities include:

• Automated filling.
• Drug-powder handling.
• Weight-based or vision-based fill verification.
• Implant-end sealing.
• Robotic assembly.
• In-process release testing.
• Device traceability.

Manufacturers capable of handling low-dose, high-value API in a sterile or controlled environment can offer contract development and manufacturing services to follow-on developers.

Applicator systems

The applicator is part of the product’s use profile. Opportunities include:

• Lower-force insertion mechanisms.
• Improved deployment control.
• Better confirmation of implant release.
• Reduced risk of incomplete delivery.
• Ergonomic redesign.
• Manufacturing-cost reduction.

An applicator redesign can create a separate intellectual-property position, but it also introduces combination-product and human-factors requirements.

What patents protect ILUVIEN and its delivery system?

ILUVIEN protection has historically relied on several overlapping categories:

1. The fluocinolone acetonide implant.
2. The non-bioerodible reservoir.
3. Controlled release over an extended period.
4. Implant dimensions and drug loading.
5. Ocular treatment methods.
6. The applicator and deployment process.
7. Manufacturing and sealing methods.

Patent scope must be evaluated by jurisdiction and by the current status of each family. Older platform patents may have expired or be nearing expiration, while later patents may cover specific dimensions, release characteristics, manufacturing steps, or delivery methods.

Patent strength by claim category

Claim category	Commercial relevance	Design-around difficulty
Fluocinolone acetonide as the API	Medium	Low
Three-year intravitreal delivery	High	Medium to high
Polyimide reservoir	High	Medium
Silicone sealing method	Medium to high	Medium
Specific implant dimensions	Medium	Medium
Applicator architecture	Medium	Low to medium
Manufacturing controls	Medium	Medium
Method of treating diabetic macular edema	High	Medium, depending on claim language

The strongest practical protection is usually the combination of drug load, reservoir dimensions, release profile, implant integrity, and applicator performance. A competitor may avoid a single patent claim yet still face regulatory difficulty demonstrating that a materially different system is equivalent.

What is the Orange Book status of ILUVIEN?

ILUVIEN is approved under an NDA and may have FDA-listed patents associated with the product. The relevant Orange Book analysis should distinguish among:

• Listed drug-substance patents.
• Drug-product patents.
• Method-of-use patents.
• Expired patents.
• Patents with remaining terms.
• Patent-use codes affecting a Paragraph IV certification.

For a generic or follow-on developer, the key regulatory route is generally an ANDA under Section 505(j), assuming the product can satisfy applicable requirements for pharmaceutical equivalence, bioequivalence, device sameness or acceptable device differences, and labeling.

ILUVIEN is not a biologic. Biosimilar approval under the Public Health Service Act does not apply. A follow-on product would more likely involve an ANDA, a 505(b)(2) application, or a full NDA if equivalence cannot be established.

When does ILUVIEN lose exclusivity?

ILUVIEN’s five-year new-chemical-entity exclusivity has expired. The commercial question is now patent and regulatory exclusivity rather than NCE exclusivity.

The main loss-of-exclusivity events are:

Event	Strategic effect
Expiration of NCE exclusivity	Permits ANDA filings if other requirements are met
Expiration of relevant product patents	Removes particular patent barriers
Expiration of method-of-use patents	Expands potential labeled or carved-out use
FDA acceptance of an ANDA	Confirms a regulatory path for a generic competitor
First commercial generic launch	Creates direct price pressure
Approval of an alternative long-acting implant	Expands substitution risk even without strict ANDA equivalence

Patent expiry dates should be assessed at the individual patent and claim level. Patent term adjustment, patent term extension, terminal disclaimers, pediatric extensions, and Orange Book delisting can alter the commercial timeline.

Which companies are challenging ILUVIEN?

No biosimilar challenge applies because ILUVIEN is a small-molecule drug-device product. Competitive pressure is more likely to come from:

• Generic drug-delivery implant developers.
• Ophthalmic implant specialists.
• Companies developing long-acting corticosteroid systems.
• Manufacturers of dexamethasone or fluocinolone products.
• Developers of sustained-release injectable or implantable delivery systems.

The most credible challenger would need capabilities in ocular clinical development, sterile manufacturing, implant engineering, and FDA combination-product submissions. Conventional generic-drug manufacturers without implant experience face a higher technical barrier.

What formulation patents and manufacturing barriers matter most?

Release-rate equivalence

A follow-on product must address more than total drug content. Relevant performance attributes include:

• Daily release rate.
• Duration of release.
• Initial burst.
• Cumulative drug release.
• Residual drug after implantation period.
• Release behavior after sterilization.
• Stability during storage.

Small differences in wall thickness, polymer permeability, drug-particle size, or seal geometry can change exposure.

Ocular biocompatibility

The implant remains in the eye for an extended period. The developer must control:

• Inflammation.
• Foreign-body response.
• Material degradation.
• Particle shedding.
• Silicone-related extractables.
• Endotoxin.
• Sterility assurance.
• Implant migration or misplacement.

The ocular route creates a lower tolerance for particulate and extractables than many systemic dosage forms.

Combination-product manufacturing

The drug, implant, and applicator must be manufactured as an integrated product. Critical process controls include:

• Reservoir dimensional inspection.
• Drug-load uniformity.
• Seal integrity.
• Applicator deployment force.
• Implant retention before use.
• Sterile-barrier integrity.
• Packaging stability.
• Particulate limits.

These requirements create a manufacturing barrier independent of patent protection.

How does ILUVIEN compare with other long-acting corticosteroid products?

Product	API	Delivery approach	Duration profile	Main competitive distinction
ILUVIEN	Fluocinolone acetonide	Non-bioerodible intravitreal implant	Up to 36 months	Long-term low-dose delivery
Retisert	Fluocinolone acetonide	Surgically implanted reservoir	Approximately 30 months	Higher-intensity corticosteroid delivery
Ozurdex	Dexamethasone	Biodegradable intravitreal implant	Approximately 3 to 6 months	Shorter duration, biodegradable system
YUTIQ	Fluocinolone acetonide	Non-bioerodible intravitreal implant	Up to 36 months	Uveitis-oriented product profile
XIPERE	Triamcinolone acetonide suspension	Suprachoroidal administration	Repeat dosing	Different route and formulation

ILUVIEN competes on dosing interval and sustained exposure. Its limitations include implant-related procedure requirements, corticosteroid-associated intraocular pressure risk, cataract risk, and the need for patient selection.

What licensing and commercial opportunities exist around ILUVIEN?

The commercial opportunity is strongest in adjacent technologies rather than direct excipient sales.

Materials and components

Companies can pursue supply or licensing arrangements covering:

• Polyimide tubing.
• Silicone sealants.
• Implant coatings.
• Drug-loading equipment.
• Sterile packaging.
• Applicator components.
• Inspection and release-testing systems.

Follow-on delivery platforms

A platform using the ILUVIEN design principles could target:

• Other corticosteroids.
• Anti-inflammatory agents.
• Anti-infective agents.
• Anti-VEGF compounds.
• Glaucoma medicines.
• Retinal diseases requiring extended exposure.

The principal development risk is that ocular implants are highly product-specific. A platform patent does not automatically establish regulatory or clinical transferability across APIs.

Contract manufacturing

A contract manufacturer with validated microassembly and ocular-device controls could support:

• Clinical-trial batches.
• Engineering lots.
• Stability programs.
• Commercial-scale assembly.
• Combination-product quality systems.

The highest-value service is integrated manufacturing, not commodity excipient supply.

What generic entry risks exist for ILUVIEN?

Generic entry would likely proceed through one of three pathways:

1. An ANDA claiming pharmaceutical equivalence and comparable implant performance.
2. A 505(b)(2) application for a modified implant, formulation, or applicator.
3. A full NDA for a substantially different long-acting ocular delivery system.

Key risks include:

• Inability to demonstrate equivalent release.
• Device differences requiring additional clinical evidence.
• Patent litigation after a Paragraph IV certification.
• Difficulty matching implant dimensions and deployment behavior.
• Inadequate long-term stability data.
• Manufacturing defects that generate particulate or seal failures.
• Limited ophthalmology commercialization infrastructure.

A generic launch after patent expiry could still be delayed by development time, manufacturing scale-up, FDA review, and physician acceptance of a new applicator.

What is the revenue exposure and competitive outlook?

ILUVIEN is commercially important because its long duration supports fewer treatment procedures than short-acting steroid implants. Revenue is exposed to five factors:

• Growth or contraction in diabetic macular edema treatment.
• Physician preference for long-acting corticosteroid therapy.
• Reimbursement and procedure economics.
• Intraocular pressure management.
• Entry by alternative sustained-release products.

ANI’s acquisition of Alimera expanded its ophthalmology portfolio and placed ILUVIEN within a larger commercial organization.[2] The product’s value is tied to its established clinical positioning, manufacturing know-how, and physician familiarity as much as to its API.

Key Takeaways

• ILUVIEN is a fluocinolone acetonide drug-device system, not a conventional excipient-based formulation.
• Polyimide and silicone are central to the product’s controlled-release and implant-integrity strategy.
• The most attractive supplier opportunities involve implant-grade materials, precision microassembly, applicators, and quality-control systems.
• ILUVIEN has no biosimilar pathway because it is a small-molecule NDA product.
• Generic entry would face technical, regulatory, manufacturing, and patent barriers.
• Patent value is concentrated in the integrated implant, release profile, applicator, and manufacturing architecture.
• The strongest commercial opportunity is a validated long-acting ocular delivery platform or specialized manufacturing capability.

FAQs

Is fluocinolone acetonide an excipient in ILUVIEN?

No. Fluocinolone acetonide is the active pharmaceutical ingredient. Polyimide and silicone are the principal implant materials associated with the delivery system.

Can polyimide in ILUVIEN be replaced with another polymer?

Potentially, but the replacement would require extensive material characterization, release testing, biocompatibility assessment, stability data, and regulatory support. A polymer change could create a new product rather than a simple formulation substitution.

Does ILUVIEN have biosimilar competition?

No. Biosimilar regulation applies to biologic products. ILUVIEN is a small-molecule fluocinolone acetonide implant approved through an NDA.

What is the most defensible follow-on product strategy for ILUVIEN?

A 505(b)(2) product using a differentiated implant, applicator, release profile, or indication may be more practical than a strict ANDA if exact device and release equivalence cannot be demonstrated.

Which ILUVIEN component creates the greatest manufacturing risk?

The integrated reservoir and seal system is the highest-risk area. Drug loading, polyimide dimensions, silicone curing, seal integrity, sterility, and particulate control directly affect product performance.

References

1. U.S. Food and Drug Administration. (2023). ILUVIEN (fluocinolone acetonide intravitreal implant) prescribing information. FDA.

2. ANI Pharmaceuticals, Inc. (2024, June 27). ANI Pharmaceuticals completes acquisition of Alimera Sciences. ANI Pharmaceuticals.

3. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides that refer to listed drugs of recombinant or naturally derived origin: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2016). Technical considerations for demonstrating biosimilarity to a reference product: Guidance for industry. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.